Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its clinical development of LUCID-MS, a proprietary therapy candidate for multiple sclerosis (MS) designed to target demyelination and protect or restore myelin integrity. The company reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
The company believes LUCID-MS may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. This mechanism could represent a significant shift in MS treatment, which currently focuses largely on immune suppression. If successful, LUCID-MS could provide a novel therapeutic option that targets the underlying pathology of MS, potentially slowing or reversing disease progression. For the estimated 2.8 million people worldwide with MS, this therapy could offer hope for improved outcomes and quality of life.
Quantum BioPharma is strengthening operational support for the program through a planned partnership with Allucent, a clinical research organization, and engagement with neurological specialists. These collaborations are intended to expedite the Phase 2 trial design and execution, bringing the therapy closer to patients. The company’s wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS, a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models.
Beyond MS, Quantum BioPharma is building a portfolio of innovative assets for challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. The company also invented unbuzzd, an over-the-counter product, and spun out its OTC version to Unbuzzd Wellness Inc. (“UWI”), led by industry veterans. Quantum BioPharma retains ownership of 19.84% (as of March 31, 2026) of UWI and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The advancement of LUCID-MS into Phase 2 trials is a critical step for Quantum BioPharma and the MS community. If the therapy proves effective, it could transform the treatment landscape by offering a disease-modifying approach that goes beyond symptom management. The company’s strategic partnerships and focus on a novel mechanism underscore its commitment to addressing unmet medical needs. Investors and stakeholders will be watching the upcoming trial results closely, as they could validate a new class of therapies for neurodegenerative diseases.
